Stock Analiz

Resmed Inc. (RMD) financials: revenue, earnings and cash flow

Fiscal 2017–2026 + TTM · from SEC filings · data as of November 13, 2026

Summary

Resmed’s revenue went from $2.1B in fiscal 2017 to $5.7B in fiscal 2026, growth of about 11.8% a year.

Net income in fiscal 2026 was $1.5B, a net margin of 26.9%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $5.7B and net income $1.6B.

Free cash flow was $1.6B in fiscal 2026 and positive in 10 of the 10 years shown.

The diluted share count rose 3% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2017: $2.1B172018: $2.3B182019: $2.6B192020: $3.0B202021: $3.2B212022: $3.6B222023: $4.2B232024: $4.7B242025: $5.1B252026: $5.7B26$5.7B
Net income
2017: $342M172018: $316M182019: $405M192020: $622M202021: $475M212022: $779M222023: $898M232024: $1.0B242025: $1.4B252026: $1.5B26$1.5B
Free cash flow
2017: $352M172018: $442M182019: $390M192020: $707M202021: $634M212022: $216M222023: $574M232024: $1.3B242025: $1.7B252026: $1.6B26$1.6B
EPS (diluted)
2017: $2.40172018: $2.19182019: $2.80192020: $4.27202021: $3.24212022: $5.30222023: $6.09232024: $6.92242025: $9.51252026: $10.4326$10.43

Income statement

Fiscal yearTTM2026202520242023202220212020201920182017
Revenue$5.7B$5.7B$5.1B$4.7B$4.2B$3.6B$3.2B$3.0B$2.6B$2.3B$2.1B
Gross profit$3.5B$3.5B$3.1B$2.7B$2.4B$2.0B$1.8B$1.7B$1.5B$1.3B$1.2B
Operating income$1.9B$1.9B$1.7B$1.3B$1.1B$1.0B$904M$810M$579M$542M$426M
Net income$1.6B$1.5B$1.4B$1.0B$898M$779M$475M$622M$405M$316M$342M
EPS (diluted)$10.98$10.43$9.51$6.92$6.09$5.30$3.24$4.27$2.80$2.19$2.40
R&D$394M$378M$331M$308M$288M$254M$225M$202M$181M$155M$144M
Revenue growth—+9.8%+9.8%+10.9%+18.0%+11.9%+8.1%+13.4%+11.4%+13.2%+12.4%

Cash flow

Fiscal yearTTM2026202520242023202220212020201920182017
Operating cash flow$1.8B$1.8B$1.8B$1.4B$693M$351M$737M$802M$459M$505M$414M
Capital spending-$162M-$156M-$90M-$99M-$120M-$135M-$103M-$95M-$69M-$63M-$62M
Free cash flow$1.6B$1.6B$1.7B$1.3B$574M$216M$634M$707M$390M$442M$352M
Dividends paid$357M$350M$311M$282M$258M$245M$227M$225M$212M$199M$186M
Buybacks$1.5B$700M$300M$150M$0$0——$23M$54M—
Stock-based pay$113M$104M$92M$80M$71M$65M$64M$58M$52M$48M$46M

Balance sheet

Fiscal yearTTM2026202520242023202220212020201920182017
Cash—$1.5B$1.2B$238M$228M$274M$295M$463M$147M$189M$822M
Debt—$826M$852M$874M$1.6B$918M$794M$1.3B$1.3B$281M$1.1B
Equity—$6.6B$6.0B$4.9B$4.1B$3.4B$2.9B$2.5B$2.1B$2.1B$2.0B
Total assets—$9.0B$8.2B$6.9B$6.8B$5.1B$4.7B$4.6B$4.1B$3.1B$3.5B
Shares (diluted)143M146M147M148M147M147M146M146M144M144M142M

Margins and returns

Fiscal yearTTM2026202520242023202220212020201920182017
Gross margin61.1%61.1%59.4%56.7%55.8%56.6%57.5%58.1%57.3%57.0%58.1%
Operating margin33.0%33.4%32.8%28.2%26.8%28.0%28.3%27.4%22.2%23.2%20.6%
Net margin27.8%26.9%27.2%21.8%21.2%21.8%14.8%21.0%15.5%13.5%16.6%
FCF margin28.1%29.2%32.3%27.8%13.6%6.0%19.8%23.9%15.0%18.9%17.0%
ROIC—20.2%20.6%18.6%16.2%19.0%13.2%18.1%13.5%14.0%11.5%
ROE—23.1%23.5%21.0%21.7%23.2%16.4%24.9%19.5%15.3%17.5%

Frequently asked questions

What is Resmed’s annual revenue?

$5.7B in fiscal 2026 and $5.7B over the twelve months to September 30, 2026.

How much profit does Resmed make?

Net income was $1.5B in fiscal 2026 (net margin 26.9%).

Is Resmed’s revenue growing?

Yes: revenue rose 9.9% in fiscal 2026 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.